Core Insights - Apyx Medical Corporation reported financial results for Q4 and the full year 2024, highlighting a decrease in total revenue but improved operational metrics and strategic initiatives [1][5][14]. Financial Performance - Total revenue for Q4 2024 was 14.2million,adecreaseof314.7 million in Q4 2023 [8]. - Advanced Energy segment revenue was approximately 12.1million,remainingflatyear−over−year,whileOEMsegmentrevenuedecreasedby162.1 million [5][8]. - For the full year 2024, total revenue decreased by 8% to 48.1millioncomparedto52.3 million in 2023 [14]. Profitability Metrics - Gross profit for Q4 2024 increased slightly to 9.0million,withagrossprofitmarginof63.04.6 million, a significant reduction of 52% from 9.6millioninQ42023[12].−AdjustedEBITDAlossforQ42024was2.2 million, down from 4.7millioninthesameperiodlastyear[13].OperationalHighlights−Thecompanyexperienceda512.0 million in Q4 2024, down from 14.7millionintheprioryear,drivenbyreductionsinvariousexpensecategories[10][16].−Thecompanyimplementedacost−savingrestructuringprogram,reducingitsU.S.workforcebynearly254.3 million [5][10]. Future Outlook - For 2025, the company projects total revenue in the range of 47.6millionto49.0 million, with Advanced Energy revenue expected between 39.6millionand41.0 million [20]. - Operating expenses are anticipated to remain below $40.0 million for the year [20].